Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.60 | N/A | +2.21% |
management commentary, guidance changes, and full analysis available with Pro.
| +2.21% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to long-term strategies despite current market challenges.
We are pleased with our EPS performance this quarter.
While we face challenges, we remain committed to our strategic goals.
Pfizer's earnings report showed a slight beat on EPS, indicating some operational strength. However, the stock dropped 4.58% in reaction, likely due to the lack of revenue figures and no guidance update, which left investors uncertain about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Aug 1, 2011